middle.news
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with Higher Dose Approval
10:52am on Wednesday 12th of November, 2025 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with Higher Dose Approval
10:52am on Wednesday 12th of November, 2025 AEDT
Key Points
Completion of second cohort enrollment in Phase 1 trial
Dose escalation to 90mCi approved for third cohort
Positive tumor uptake observed in initial patients
Favorable safety profile reported so far
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE